AU2015349687B2 - Fused bicyclic compounds for the treatment of disease - Google Patents

Fused bicyclic compounds for the treatment of disease Download PDF

Info

Publication number
AU2015349687B2
AU2015349687B2 AU2015349687A AU2015349687A AU2015349687B2 AU 2015349687 B2 AU2015349687 B2 AU 2015349687B2 AU 2015349687 A AU2015349687 A AU 2015349687A AU 2015349687 A AU2015349687 A AU 2015349687A AU 2015349687 B2 AU2015349687 B2 AU 2015349687B2
Authority
AU
Australia
Prior art keywords
optionally substituted
compound
formula
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015349687A
Other languages
English (en)
Other versions
AU2015349687A1 (en
Inventor
Raju Mohan
Benjamin Anthony PRATT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akarna Therapeutics Ltd
Original Assignee
Akarna Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarna Therapeutics Ltd filed Critical Akarna Therapeutics Ltd
Publication of AU2015349687A1 publication Critical patent/AU2015349687A1/en
Application granted granted Critical
Publication of AU2015349687B2 publication Critical patent/AU2015349687B2/en
Priority to AU2020250270A priority Critical patent/AU2020250270B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2015349687A 2014-11-21 2015-11-20 Fused bicyclic compounds for the treatment of disease Ceased AU2015349687B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020250270A AU2020250270B2 (en) 2014-11-21 2020-10-08 Fused bicyclic compounds for the treatment of disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462083031P 2014-11-21 2014-11-21
US62/083,031 2014-11-21
PCT/US2015/062017 WO2016081918A1 (en) 2014-11-21 2015-11-20 Fused bicyclic compounds for the treatment of disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020250270A Division AU2020250270B2 (en) 2014-11-21 2020-10-08 Fused bicyclic compounds for the treatment of disease

Publications (2)

Publication Number Publication Date
AU2015349687A1 AU2015349687A1 (en) 2017-06-29
AU2015349687B2 true AU2015349687B2 (en) 2020-07-09

Family

ID=56014622

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015349687A Ceased AU2015349687B2 (en) 2014-11-21 2015-11-20 Fused bicyclic compounds for the treatment of disease
AU2020250270A Ceased AU2020250270B2 (en) 2014-11-21 2020-10-08 Fused bicyclic compounds for the treatment of disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020250270A Ceased AU2020250270B2 (en) 2014-11-21 2020-10-08 Fused bicyclic compounds for the treatment of disease

Country Status (17)

Country Link
US (5) US10233187B2 (2)
EP (1) EP3221321B1 (2)
JP (3) JP7224102B2 (2)
KR (1) KR20170117020A (2)
CN (2) CN111662297A (2)
AU (2) AU2015349687B2 (2)
CA (1) CA2968434A1 (2)
CL (1) CL2017001289A1 (2)
CO (1) CO2017005784A2 (2)
ES (1) ES2911293T3 (2)
IL (1) IL252309B (2)
MX (1) MX370480B (2)
MY (1) MY192927A (2)
RU (1) RU2706007C2 (2)
SA (1) SA517381566B1 (2)
SG (2) SG11201703953WA (2)
WO (1) WO2016081918A1 (2)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
CR20170076A (es) 2014-08-04 2017-06-26 Nuevolution As Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
ES2911293T3 (es) * 2014-11-21 2022-05-18 Akarna Therapeutics Ltd Compuestos bicíclicos fusionados para el tratamiento de enfermedades
WO2016151403A1 (en) * 2015-03-26 2016-09-29 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
EP3463373A4 (en) * 2016-05-25 2020-04-22 Akarna Therapeutics, Ltd. COMBINATION THERAPIES WITH FARNESOID-X RECEPTOR (FRX) MODULATORS
BR112018075734A2 (pt) 2016-06-13 2019-04-02 Gilead Sciences, Inc. composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
CN110461328A (zh) 2017-03-28 2019-11-15 吉利德科学公司 治疗肝疾病的治疗组合
WO2018222876A1 (en) * 2017-06-02 2018-12-06 Akarna Therapeutics, Ltd. Fused bicyclic compounds
EP4360632B1 (en) 2019-01-15 2025-10-29 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
US11524005B2 (en) 2019-02-19 2022-12-13 Gilead Sciences, Inc. Solid forms of FXR agonists
CN111825653A (zh) * 2019-04-19 2020-10-27 安道麦马克西姆有限公司 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途
CN114080234A (zh) 2019-07-23 2022-02-22 诺华股份有限公司 包含fxr激动剂的治疗
EP4003349A1 (en) 2019-07-23 2022-06-01 Novartis AG Combination treatment of liver diseases using fxr agonists
CA3153062A1 (en) 2019-09-03 2021-03-11 Novartis Ag Treatment of liver disease or disorder comprising actrii receptor antagonists
WO2021053618A1 (en) 2019-09-19 2021-03-25 Novartis Ag Treatment comprising fxr agonists
EP4041233A1 (en) 2019-09-30 2022-08-17 Novartis AG Treatment comprising the use of fxr agonists
AU2020405446A1 (en) 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
TW202135811A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 使用整聯蛋白抑制劑組合治療肝臟疾病
AU2020408107B2 (en) 2019-12-20 2026-04-23 Nuevolution A/S Compounds active towards nuclear receptors
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
EP4126874A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
AR123313A1 (es) * 2020-08-24 2022-11-16 Adama Makhteshim Ltd Proceso para la preparación de pirazoles sustituidos
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015746A1 (en) * 2003-07-23 2007-01-18 X-Ceptor Therapeutics Inc. Azepine derivaties as pharmaceutical agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
DE602004019118D1 (de) 2003-09-17 2009-03-05 Janssen Pharmaceutica Nv Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
US20090137554A1 (en) * 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
US20090215748A1 (en) * 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
WO2010036362A1 (en) 2008-09-26 2010-04-01 Wyeth 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
US8252826B2 (en) 2010-03-24 2012-08-28 Hoffmann-La Roche Inc. Cyclopentyl- and cycloheptylpyrazoles
ES2911293T3 (es) * 2014-11-21 2022-05-18 Akarna Therapeutics Ltd Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112018074231A2 (pt) * 2016-05-25 2019-03-06 Akarna Therapeutics, Ltd. compostos bicíclicos fundidos para o tratamento de doença

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015746A1 (en) * 2003-07-23 2007-01-18 X-Ceptor Therapeutics Inc. Azepine derivaties as pharmaceutical agents

Also Published As

Publication number Publication date
SG10202010386PA (en) 2020-11-27
US20210147426A1 (en) 2021-05-20
US20250171446A1 (en) 2025-05-29
WO2016081918A1 (en) 2016-05-26
KR20170117020A (ko) 2017-10-20
HK1244802A1 (zh) 2018-08-17
CA2968434A1 (en) 2016-05-26
AU2020250270A1 (en) 2020-11-05
JP7224102B2 (ja) 2023-02-17
RU2017121588A3 (2) 2019-05-21
JP2021011482A (ja) 2021-02-04
US10233187B2 (en) 2019-03-19
AU2015349687A1 (en) 2017-06-29
CN107207513B (zh) 2020-07-28
JP2017535614A (ja) 2017-11-30
EP3221321B1 (en) 2021-12-15
ES2911293T3 (es) 2022-05-18
EP3221321A1 (en) 2017-09-27
CL2017001289A1 (es) 2018-03-02
CN111662297A (zh) 2020-09-15
BR112017010627A2 (pt) 2018-02-14
SA517381566B1 (ar) 2021-05-16
SG11201703953WA (en) 2017-06-29
MX370480B (es) 2019-12-16
RU2706007C2 (ru) 2019-11-13
US20190308977A1 (en) 2019-10-10
RU2017121588A (ru) 2018-12-24
JP2023011731A (ja) 2023-01-24
IL252309B (en) 2021-01-31
EP3221321A4 (en) 2018-04-25
IL252309A0 (en) 2017-07-31
US20170355699A1 (en) 2017-12-14
MY192927A (en) 2022-09-15
US20230183247A1 (en) 2023-06-15
CN107207513A (zh) 2017-09-26
MX2017006694A (es) 2018-03-16
CO2017005784A2 (es) 2017-10-31
AU2020250270B2 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
AU2020250270B2 (en) Fused bicyclic compounds for the treatment of disease
AU2015370588B2 (en) Fused bicyclic compounds for the treatment of disease
AU2020256301A1 (en) Fused bicyclic compounds for the treatment of disease
HK40049146A (en) Fused bicyclic compounds for the treatment of disease
HK1244802B (en) Fused bicyclic compounds for the treatment of disease
HK1245795B (en) Fused bicyclic compounds for the treatment of disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired